Monday, May 28, 2007

Pharmion (Schering AG)





Refludan® for the treatment of heparin-induced thrombocytopenia type II and thromboembolic disease in adults mandating parenteral antithrombin therapy - an infrequent but potentially life-threatening response to heparin therapy

No comments: